Biosensor Recession proof -heartstent biz

  • mardi.tan@yahoo.com.sg
  • Visitor
  • Visitor
11 years 6 months ago #11861 by mardi.tan@yahoo.com.sg
Replied by mardi.tan@yahoo.com.sg on topic Re:Biosensor Recession proof -heartstent biz
This counter sure down again,,,,,,,,
die now,, hold too much

Please Log in or Create an account to join the conversation.

  • Trader
  • Visitor
  • Visitor
11 years 6 months ago #11893 by Trader
haha! i told you.... was $1.055, now $1.135
[hr]
[trader 01-11-2012]:

Incredible value at now $1.055

Please Log in or Create an account to join the conversation.

  • Kiasu
  • Visitor
  • Visitor
11 years 6 months ago #11898 by Kiasu
It's alredi 1.155. I bought at 1.04 after your call. It can go above 1.23, which is the support level for the past few mths. Thanks Trader for the call. Good luck to you and all.  

Please Log in or Create an account to join the conversation.

  • trader
  • Visitor
  • Visitor
11 years 6 months ago #11939 by trader
CIMB this morning said:

Biosensors’ share price has taken a beating from earnings worries following news of |Terumo’s weak licensing fee to BIG. Management shrugged it off as a 2Q blip and reiterated its strong revenue guidance. 2Q/1HFY13 core net profit was broadly in line, at 23%/46% of our full-year forecasts and 20%/39% of consensus numbers.

|Nevertheless, we cut FY3/13 earnings and our SOP target price to reflect the risk of |weaker licensing income from Japan and potential price cuts in various countries.|This does not affect our Outperform call as product profitability remains strong and valuations are really palatable now. Tgt. S$1.79

Please Log in or Create an account to join the conversation.

  • Guest
  • Visitor
  • Visitor
11 years 6 months ago #11940 by Guest
BioSensors reported the 2Q13 result today, with rev +28%. Drug-eluting stent (DES) sales remained strong in Europe with double-digit growth, despite the global market size seeing a single-digit decline. Licensing revenue from Terumo declined 29% YoY but it seems to be a temporary dip due to competing products launched in 1H12 but no more launches are expected in 2H12. The renewed contract term with Terumo is better than before as it has downside protection plus unlimited upside. Gross margin increased from 80.7% to 83.7% on a YoY basis. DES will account for a higher portion of total revenue, and CS expect the improvement in gross margin to be sustainable if it could continue the product mix changes. Globally, DES market continues to shrink. Boston Scientific’s DES rev saw a 24% YoY decline in 3Q12. Although Biosensors still has a much smaller market share than Abbott and Boston Scientific in the global mkt, it’s DES revenue continues to grow above 10%. Ratings as follow: CS maintains O/p with $1.80 TP. OCBC maintains Buy with $1.69 TP

Please Log in or Create an account to join the conversation.

  • Trader
  • Visitor
  • Visitor
11 years 6 months ago #11949 by Trader
Biosensors has done something to boost confidence of investos. Today, it bought back 1.5 million shares @ ave of $1.1127

Please Log in or Create an account to join the conversation.

Time to create page: 0.224 seconds
Powered by Kunena Forum
 

We have 254 guests and no members online

rss_2 NextInsight - Latest News